12:28 PM
 | 
Sep 07, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Anti-aging Elevian debuts with $5.5M seed funding

Editor's Note: This article was updated on Sep 10, 2018 at 11:27 AM PDT

Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors.

Elevian aims to develop therapeutics that increase levels of growth differentiation factor 11 (GDF11) to treat diseases associated with aging, such as coronary artery disease, Alzheimer's disease, Type II diabetes and sarcopenia.

In a 2013 Cell

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >